Realyze Intelligence, incubated at and funded by UPMC Enterprises, provides a platform that uses EMR data to identify chronic disease patients and help clinicians link them to appropriate treatment options. The platform leverages not only the structured data available in EMRs but also unstructured clinical notes.
E-Mail
IMAGE: Associate professor in Pitt s Division of Infectious Diseases and director of the UPMC Community Hospital Antimicrobial Stewardship Efforts (CHASE) Program. view more
Credit: UPMC
PITTSBURGH, May 17, 2021 - Monoclonal antibodies, a COVID-19 treatment given early after coronavirus infection, cut the risk of hospitalization and death by 60% in those most likely to suffer complications of the disease, according to an analysis of UPMC patients who received the medication compared to similar patients who did not.
UPMC and University of Pittsburgh School of Medicine physician-scientists published the findings today in Open Forum Infectious Diseases, a journal of the Infectious Diseases Society of America. The study involved bamlanivimab, a monoclonal antibody that is now offered only in combination with another monoclonal antibody to further increase its effectiveness a change mandated by the federal government after the study s completion.
Date Time
Breast Cancer Treatment in Those Over 70 Can Be Reduced
Oncologists faced with treating older women with breast cancer often must decide if the treatment may be more detrimental than the cancer. A study published today in JAMA Network Open by researchers at UPMC Hillman Cancer Center and the University of Pittsburgh School of Medicine sheds new light on this choice and suggests the rate of cancer recurrence or survival may be no different in treated vs. untreated elderly patients diagnosed in the early stages of the cancer diagnosed most commonly in women.
“As a breast surgeon, I want to give my patients the best chance of survival with the best quality of life,” said senior author Priscilla McAuliffe, M.D., Ph.D., surgical oncologist at UPMC Hillman Cancer Center and attending surgeon in the Department of Surgery at Pitt. “However, we have found that overtreatment of early-stage breast cancer in older patients may actually cause harm while not improving recurrence
E-Mail
IMAGE: Surgical oncologist at UPMC Hillman Cancer Center and attending surgeon in the Department of Surgery, University of Pittsburgh. view more
Credit: UPMC
PITTSBURGH, April 15, 2021 - Oncologists faced with treating older women with breast cancer often must decide if the treatment may be more detrimental than the cancer. A study published today in
JAMA Network Open by researchers at UPMC Hillman Cancer Center and the University of Pittsburgh School of Medicine sheds new light on this choice and suggests the rate of cancer recurrence or survival may be no different in treated vs. untreated elderly patients diagnosed in the early stages of the cancer diagnosed most commonly in women.